GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2006

BMS and Gilead Agree to Commercialize Atripla in Canada

  • Bristol-Myers Squibb and Gilead Sciences signed an agreement to commercialize Atripla™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada for adults with HIV-1, subject to Health Canada’s approval. Atripla is the first once-daily, single-tablet regimen for HIV.

    This agreement expands the companies’ U.S. joint venture established in December 2004. The companies will together complete regulatory filings in Canada and will share responsibility for commercialization in Canada. As in the U.S., both companies will provide funding and field-based sales representatives to promote Atripla.

    Atripla combines Bristol’s Sustiva® (efavirenz) and Gilead’s Truvada® (emtricitabine and tenofovir disoproxil fumarate), itself a fixed-dose reformulation of Gilead’s Viread® and Emtriva®. Atripla is intended as a stand-alone therapy or in combination with other antiretrovirals.

    Gilead will record revenues from future net sales of Atripla, and Bristol-Myers Squibb will record revenues at percentages relative to the contribution represented by its individual product.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »